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Abstract: Mercury exhibits cytotoxic and mutagenic properties as a result of its effect on 
tubulin. This toxicity mechanism is related to the production of free radicals that can cause 
DNA damage. Methylmercury (MeHg) is one of the most toxic of the mercury compounds. 
It accumulates in the aquatic food chain, eventually reaching the human diet. Several 
studies have demonstrated that prolactin (PRL) may be differently affected by inorganic 
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and organic mercury based on interference with various neurotransmitters involved in the 
regulation of PRL secretion. This study evaluated the cytoprotective effect of PRL on 
human lymphocytes exposed to MeHg in vitro, including observation of the kinetics of 
HL-60 cells (an acute myeloid leukemia lineage) treated with MeHg and PRL at different 
concentrations, with both treatments with the individual compounds and combined 
treatments. All treatments with MeHg produced a significant increase in the frequency of 
chromatid gaps, however, no significant difference was observed in the chromosomal 
breaks with any treatment. A dose-dependent increase in the mitotic index was observed 
for treatments with PRL, which also acts as a co-mitogenic factor, regulating proliferation 
by modulating the expression of genes that are essential for cell cycle progression and 
cytoskeleton organization. These properties contribute to the protective action of PRL 
against the cytotoxic and mutagenic effects of MeHg. 
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1. Introduction 
In the environment there are different forms of mercury (Hg), including the metallic element itself, 
inorganic compounds, and derivatives of Hg such as thimerosal. When introduced in Nature, these 
compounds may undergo various transformations. Inorganic mercury can be transformed into 
methylmercury (MeHg) and other compounds through the action of methanogenic bacteria. This type 
of biological transformation represents a serious risk to the environment because biotransformed 
mercury compounds (such as MeHg) tend to accumulate in the aquatic environment, reaching the food 
chain, where they can potentially reach the human diet [1]. 
The potential of Hg as a source of environmental contamination that affects humans in different 
parts of the world is widely accepted. Riverside populations in the Amazon have been widely exposed 
to amounts of MeHg above the recommended levels for many years due to the use of Hg to retrieve 
gold in gold mining processes and also by the existence of natural sources of Hg in the Amazon [2–4]. 
The effects of long term to Hg exposure are still poorly known and not well understood, but their 
potential genotoxicity revealed in both in vitro and in epidemiological studies has been described [2]. 
The mutagenic effects of Hg and its organomercurial compounds particularly affect tubulin, which 
forms the subunit of microtubules, affecting the organization of the cytoplasm and the formation of the 
spindle fibers, which in turn affect cell division. The mercury acts in a manner that is detrimental to tubulin 
polymerization, which leads to a delays in anaphasic movement, centromeric division and contraction of 
the chromosomes in metaphase [5], and may lead to chromosomal abnormalities such as polyploidy [6–8].  
Mercury compounds induce a general collapse of the antioxidant mechanisms in the cell by binding to 
the sulfhydryl groups of glutathione peroxidase, a major selenoenzyme with antioxidant properties. Such 
a collapse results in cell degeneration inhibits lipid peroxidation and thereby induces loss of membrane 
integrity and finally cell necrosis, which can be indicated by a decrease in the mitotic index [9]. One of 
the important mechanisms of the genotoxicity of MeHg is its action on the production of free radicals 
that can cause permanent damage to DNA [10]. MeHg is classified in Group 2B by the International 
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Agency for Research on Cancer (IARC), which indicates that it is a potential cancer-causing agent in 
humans [11]. 
MeHg also induces neurotoxicity and apoptosis [12]. It promotes an increase in the formation of 
reactive radicals, accelerating the reactions of free radicals, thus inducing neurotoxicity. The process of 
oxidative stress in the central nervous system can lead to damage to several mechanisms of cellular 
interaction: mitochondrial collapse, increases in free Ca2+ levels within cells (similar to the effect of 
lead [13]), alterations in the mechanisms of enzyme activation and inactivation, release of amino acids, 
expression of several metallothioneins, and breakdown of the structure of microtubules [9,14]. In vivo 
exposure to Hg alters a specific neurochemical process at the nucleotide level. Chronic low-level Hg 
exposure markedly inhibits the binding of GTP (guanosine 5'-triphosphate) to brain β-tubulin,  
an essential step in the formation of microtubules [15].  
Some studies have demonstrated an inverse relationship between the levels of urinary Hg and serum 
PRL (PRLS). Lucchini et al. [16] observed that PRLS function decreased as both Hg excreted in urine 
and occupational exposure to inorganic Hg increased. Additionally, an interesting article was 
published by de Burbure et al. [17] on the health effects of living near smelters of nonferrous metals 
(lead, cadmium, mercury, and arsenic) in children in France, the Czech Republic and Poland. This 
study demonstrated that all four metals influenced the dopaminergic markers PRLS. 
In another study, however, Carta et al. [18] observed the opposite effect on PRL in adult subjects 
with a high intake of tuna fish contaminated with Hg. In this investigation, PRLS levels were 
positively associated with urinary and blood Hg. According to the interpretation of Alessio and 
Lucchini [19], this dual behavior may be due to PRL being affected in different ways by different 
species of Hg (organic and inorganic) and also based on the interference relationship with various 
types of various neurotransmitters involved in the regulation of PRL release. 
In the present study, we investigated the effects of PRL on cultured human lymphocytes and 
evaluated the cytoprotective effect of PRL in these lymphocytes exposed to MeHg. Furthermore,  
we observed the cell cycle kinetics of the leukemic HL-60 cell line treated with PRL and MeHg under 
different concentrations with simple and conjugated treatments. 
2. Experimental Section  
2.1. Culture of Human Healthy Lymphocytes 
Blood samples were obtained from eight healthy nonsmoker volunteers, four females and four 
males aged 20–50 years, with no recent history of infectious disease, no exposure to medicinal drugs, 
and no treatment with chemotherapy, radiation, or hormones. This study was approved by the Ethics 
Committee of Núcleo de Medicina Tropical, Belem, Brazil (001/2007-CEP/NMT). Participants were 
required to provide information on their personal data and their lifestyles (dietary habits, tobacco 
smoking, alcohol consumption and drug use) based on a modified version of the Commission for 
Protection against Environmental Mutagens and Carcinogens questionnaire [20].  
Cultures were prepared with 1 mL plasma in 5 mL of culture medium consisting of 80% RPMI-1640 
medium (Gibco, Paisley, UK), 20% fetal calf serum (Cultilab, Campinas, SP, Brazil) with antibiotics 
(100 IU penicillin/mL and 100 μL streptomycin/mL, Gibco) and 4% phytohemagglutinin (Cultilab). 
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Human lymphocytes were cultured for two days (48 h). Metaphase preparations were obtained using 
the human lymphocyte culture techniques described in Moorhead et al. [21], with modifications 
introduced by Lima et al. [22]. To obtain a sufficient number of analyzable metaphases, colchicine  
(0.8 mM; Sigma Aldrich Co., St. Louis, MO, USA) was added to the cultures 1.5 h before harvest.  
The cells were harvested using centrifugation and were treated with 0.075 M KCl at 37 °C for 20 min. 
The cells were then centrifuged and fixed in 1:3 (v/v) acetic acid-methanol. Finally, slides were 
prepared, air-dried and stained with 3% Giemsa solution (pH 6.8) for 8 min. 
2.2. Culture of the HL-60 Leukemia Cell Line  
The HL-60 promyelocytic leukemia cell line (American Type Culture Collection—Rockville, MD, 
USA) was maintained in medium consisting of RPMI 1640 (Gibco), containing 10% fetal calf serum 
(Cutilab) with antibiotics (200 UI penicillin/mL and 0.2 mg streptomycin/mL and 50 μg gentamicin/mL, 
Gibco) and human insulin (5 μg/mL). Cultures were incubated at 37 °C and 6% CO2. 
2.3. Treatment of Cultures 
For the cytogenetic analysis, the cultures were incubated in a water-bath at 37 °C for 48 h. 
Treatments were performed with CH3HgCl (Ultra Scientific®, North Kingstown, RI, USA) and PRL 
(Sigma-Aldrich), both diluted in distilled water. The concentrations displayed in Table 1 were added to 
each culture 9 h after the beginning of the incubation.  
Table 1. Description of in vitro treatments with methylmercury chloride and prolactin on 
human healthy lymphocytes and HL-60 leukemic cell line. 
Treatment (T) CH3HgCl [μΜ] PRL [nΜ] Doxorubicin * [μM] 
T1 (C−) - - - 
T2 50 - - 
T3 100 - - 
T4 500 - - 
T5 1000 - - 
T6 - 1 - 
T7 - 10 - 
T8 - 100 - 
T9 50 10 - 
T10 500 10 - 
T11 50 100 - 
T12 500 100 - 
T13 - - 0.010 
CH3HgCl = methylmercury chloride; PRL = Prolactin; (C−) = Untreated; (*) = Positive 
control, used only for the HL60 cell line. Cells were harvested using centrifugation 
(300 g), treated for 10 min with 0.075 M KCl (Merck, Darmstadt, Germany), and fixed 
with 1:3 Carnoy fixative (glacial acetic acid:absolute methanol). Slides were prepared, 
air-dried, and stained for 5 min with 3% Giemsa stain (Merck) diluted in buffer 
solution, pH 6.8. 
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The slides were then coded and scored in a blind manner using light microscopy. Eight hundred 
metaphases per treatment were observed for the analysis of chromosome abnormalities (gaps and 
breaks). The polyploidy index was calculated by counting a total of 1000 cells (regardless of their 
stage in the cell cycle) at each concentration, using the formula polyploidy index = (number of 
polyploid cells/total number of cells) × 100. The mitotic index was calculated by counting a total of 
3000 cells at each concentration using the formula mitotic index = (number of cells in division/total 
number of cells) × 100. 
Two statistical tests were used for the analysis of chromosome abnormalities: chi-square for the 
proportion of abnormal cells and Mann-Whitney U-test for the frequency of gaps and breaks in control 
vs. each treatment (total number of abnormalities per 100 cells). A cell with two or more abnormalities 
was counted as one for the chi-square test but as two or more abnormalities for the Mann-Whitney test. 
The chi-square test was also used to identify the differences in the frequency of polyploidy and mitotic 
index between treated cultures and controls. Sperman’s test was employed for correlation analysis 
between the concentrations and the mitotic index. Statistical analyses were conducted using the 
Statistica software (StatSoft Inc., Tulsa, OK, USA, 2000) [23]. 
3. Results and Discussion 
3.1. Mutagenic Effects 
Table 2 summarizes the results of the analysis of structural chromosomal aberration levels in 
peripheral human lymphocytes in culture treated with different concentrations of MeHg and PRL.  
Two parameters were observed independently and in combination: chromatid gaps and chromosome 
breaks. Although gaps do not yield acentric fragments as true discontinuities of the chromosome 
structure, we decided to include the gaps analysis in this study because its use as a parameter for 
assessing mutagenic effects is still controversial in the literature [24]. When compared with the 
negative control, all MeHg treatments showed a significant increase in the frequency of chromatid 
gaps; however, no statistically significant difference was observed in the frequency of chromosomal 
breaks in any treatment. The huge difference between the number of gaps and breaks can be explained 
by the fact that cells remain in contact with MeHg for 48 h only (one cell cycle). It is likely that in 
culture lasting 72 h, the number of breaks may increase. 
The short duration (48 h) cultures in this experiment could also explain the similarities of the results 
found in lymphocytes and HL-60, although HL-60 is a cancerous cell line. It is likely that in long  
term cultures (over 72 h), differences in the response to MeHg treatment between neoplastic and  
non-neoplastic cells may appear. Moreover, as housekeeping proteins interacts with MeHg, such as 
tubulin, actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the effect of MeHg in  
non-neoplastic and neoplastic cells may be similar [25]. 
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Table 2. Relative frequency of healthy human lymphocytes with gaps, breaks, and gaps 
plus breaks after exposure to methylmercury chloride and prolactin. 
Treatment 
Gaps  Breaks  Total 
P 
N° FR (%)  N° FR (%)  N° FR (%) 
T1 = C− 4 0.50  0 0.00  4 0.50 (-) 
T2 57 7.13 *  2 0.25 NS  59 7.38 * (-) 
T3 32 4.00 *  2 0.25 NS  36 4.50 * (-) 
T4 82 10.25 *  3 0.38 NS  87 10.88 * (-) 
T5 118 14.75 *  4 0.50 NS  122 15.25 * (-) 
T6 1 0.13 *  0 0.00 NS  1 0.13 * (-) 
T7 3 0.38  1 0.13 NS  4 0.50 (-) 
T8 2 0.25 *  0 0.00 NS  2 0.25 * (-) 
T9 54 6.75 *  2 0.25 NS  56 7.00 * 
vs. T2 NS 
vs. T7 ** 
T10 75 9.38 *  1 0.13 NS  76 9.50 * 
vs. T4 NS 
vs. T7 ** 
T11 54 6.75 *  1 0.13 NS  55 6.88 * 
vs. T2 NS 
vs. T8 ** 
T12 80 10.00 *  2 0.25 NS  82 10.25 * 
vs. T4 NS 
vs. T8 ** 
T = Treatment; C− = Negative Control; FR = Relative Frequency.; N° = Number. *P < 0.05 comparing to 
the negative control; **P< 0.05 comparing treatments. The Chi-Square test was used for proportions of 
abnormal cells, and the U Mann-Whitney test for the relative frequency of gaps and breaks (total number 
of changes per 100 cells). NS = not statistically significant. (-) = no comparison. 
There was also no significant difference in the frequency of structural aberrations between MeHg 
treatments and their simultaneous MeHg and PRL treatment. This suggests that in this experiment,  
the hormone was not able to protect cells against Hg compounds. 
Rania et al. [26] evaluated the genotoxic effect of two concentrations (100 and 1000 μg/L) of MeHg 
in cultured human lymphocytes. As a result, a significant increase in the frequency of chromosome 
aberrations (both gaps and breaks) and exchanges between sister chromatids was observed at both 
concentrations. Researchers have also investigated the cytoprotective role of vitamin C on mercury 
compounds-induced genotoxicity in human lymphocyte cultures and obtained significant results. 
Table 3 shows that compared to the negative control, all MeHg and MeHg + PRL treatments 
produced significantly different results regarding polyploidy in the lymphocytes. In comparisons 
between the treatments, only T2 (cells treated with 50 μM of MeHg) did not differ significantly from 
simultaneous treatment with PRL. 
When we evaluated the percentage of polyploid cells in the HL-60 strain, we observed significant 
differences for all MeHg treatments compared to the negative control. The null result shown in  
Tables 2‒4 for the T5 treatment was due to the death of HL-60 cells treated with the highest 
concentration of MeHg. The positive control (doxorubicin 0.010 μM) also showed significantly 
different results from the MeHg treatments. 
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Table 3. Distribution of cells with polyploid aberrations (%) following exposure to 
different concentrations of methylmercury chloride and prolactin. 
Treatment 
 Lymphocytes  Cell Line HL-60 
 Polyploid Index (%)  P  Polyploid Index (%)  P 
T1(C−)  4.57 ± 2.2254  (-)  7.13 ± 1.2543   (-) 
T2  21.71 ± 5.2509 *  (-)  24.00 ± 5.6327 * #  (-) 
T3  37.14 ± 3.9761 *  (-)  32.20 ± 3.2659 * #  (-) 
T4  42.86 ± 2.7343 *  (-)  42.86 ± 2.3652 * #  (-) 
T5  60.14 ± 3.4365 *  (-)  0.00 ± 0.0000 * #  (-) 
T6  3.43 ± 1.7183   (-)  5.15 ± 1.3266   (-) 
T7  5.86 ± 1.9518   (-)  8.08 ± 1.9688   (-) 
T8  9.00 ± 1.9149   (-)  10.00 ± 3.1255   (-) 
T9  20.57 ± 1.6184 *  vs. T2 NS  
vs. T7 ** 
 22.42 ± 5.9644 * #  vs. T2 **  
vs. T7 ** 
T10  38.14 ± 2.9114 *  vs. T4 **  
vs. T7 ** 
 39.14 ± 3.9159 * #  vs. T4 **  
vs. T7 ** 
T11  26.00 ± 2.7080 *  vs. T2 NS  
vs. T8 ** 
 25.24 ± 2.3650 * #   vs. T2 NS  
vs. T8 ** 
T12  35.86 ± 2.7946 *  vs. T4 **  
vs. T8 ** 
 37.63 ± 5.6329 * #  vs. T4 **  
vs. T8 ** 
T13(C+)  (-)  (-)   6.33 ± 1.8247 *  (-) 
Data are reported as the mean ± SD. *P < 0.05 compared to control (chi-square test); **P < 0.05 for data 
compared between treatments (chi-square test); #P < 0.05 compared to positive control—Doxorubicin  
0.010 μM (chi-square test). NS = not statistically significant. (-) = no comparison. 
The increased incidence of polyploidy observed in the treatments with increasing concentrations of 
MeHg confirms the characteristic effect of MeHg compounds on mitotic spindles. The strong affinity 
of MeHg for sulfhydryl groups located on the spindle impairs spindle function, leading to errors in 
chromosome segregation during cell division and consequently to polyploidy [6–8,27]. 
In most cases, exposure to PRL reduced the induction polyploidy caused by MeHg, indicating a 
protective action against this mutagenic effect of Hg. The only treatment that produced no significant 
difference was 50 μM of MeHg + 100 nM of PRL (T11) compared with treatment with the same 
concentration of MeHg alone (T2). Generally, after treatments with MeHg and PRL, the frequency of 
polyploidy in the leukemic strain was slightly higher than in the groups of lymphocytes, but this difference 
was not statistically significant. 
3.2. Cytotoxic Effects 
Table 4 shows that the mean mitotic index obtained from the analysis of the 3000 cells/concentration 
ranged from 1.60% to 5.43% in the lymphocytes and from 0.00% to 4.40% in the HL-60 leukemic cell 
line. The cytotoxic effects of MeHgCl were relatively more pronounced, as demonstrated by a 
significant dose-related decrease in the mitotic index following exposure to this compound, with 
negative correlations based on the Sperman’s test for both lymphocytes (RS = −0.7465; p = 0.1473) and 
the HL-60 cell line (RS = −0.9883; p = 0.0015), although only significant for neoplastic cells (Figure 1). 
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A dose-dependent increase in the mitotic index was observed for the PRL treatments. Although no 
significant differences were observed, the MI is often lower in the HL-60 cells than in the 
lymphocytes, most likely because MeHg has a greater cytotoxic effect on the HL-60 leukemic cells 
because, in theory, they have a faster cell cycle than lymphocytes.  
Table 4. Mean mitotic index (%) of healthy human lymphocytes and HL-60 leukemic cells 
treated with different concentrations of methylmercury chloride and prolactin. 
Treatment 
 Lymphocytes  Cell Line HL-60 
 Mitotic Index (%)  P  Mitotic Index (%)  P 
T1(C−)  3.89 ± 0.6440  (-)  3.80 ± 0.3247 #  (-) 
T2  3.40 ± 0.5196 NS  (-)  3.60 ± 0.5236 NS #  (-) 
T3  2.13 ± 0.3904 *  (-)  3.30 ± 0.3934 NS #  (-) 
T4  1.60 ± 0.4000 *  (-)  1.30 ± 0.5254 *  (-) 
T5  1.70 ± 0.5657 *  (-)  0.00 ± 0.0000 * #  (-) 
T6  3.76 ± 0.5769 NS  (-)  3.60 ± 0.4246 NS #  (-) 
T7  4.93 ± 0.6020 *  (-)  4.00 ± 0.3639 NS #  (-) 
T8  5.43 ± 0.6499 *  (-)  4.40 ± 0.5896 NS #  (-) 
T9  3.57 ± 0.5880 NS  
vs. T2 NS  
vs. T7 ** 
 3.70 ± 0.3262 NS #  
vs. T2 NS  
vs. T7 NS 
T10  2.66 ± 0.5381 *  
vs. T4 **  
vs. T7 ** 
 2.60 ± 0.3588 *  
vs. T4 **  
vs. T7 ** 
T11  3.64 ± 0.4577 NS  
vs. T2 NS  
vs. T8 ** 
 4.20 ± 0.4856 NS #  
vs. T2 NS  
vs. T8 NS 
T12  2.26 ± 0.3960 *  
vs. T4 **  
vs. T8 ** 
 2.90 ± 0.3699 * #  
vs. T4 **  
vs. T8 ** 
T13(C+)  (-)  (-)  1.90 ± 0.4529 *  (-) 
Data are reported as the mean ± SD. *P < 0.05 compared to control (chi-square test); **P < 0.05 for data 
compared between treatments (chi-square test); #P < 0.05 compared to positive control—Doxorubicin  
0.010 μM (chi-square test); NS = not statistically significant; (-) = no comparison. 
Based on the analysis of the mitotic index of the HL-60 leukemic strain, treatments with lower 
concentrations of MeHg (50 and 100 μM) showed no cytotoxicity in this system. Similarly, PRL at all 
concentrations tested showed no statistically significant changes. However, when evaluating the 
highest concentrations (500 and 1000 μM) of MeHg, we found a significant increase in the cytotoxic 
effect (P < 0.05) compared to the negative control. The positive control (doxorubicin 0.010 μM) 
demonstrated an effect that was significantly different from all other treatments, including the negative 
control. In evaluating MeHg treatment, 50 μM MeHg alone or combined with PRL produced no 
significant change in the mitotic index compared to the negative control. On the other hand, as 
observed in the cultured lymphocytes, PRL reduced the cytotoxicity induced in the HL-60 cells by  
500 μM MeHg. 
For decades, it has been shown that MeHg disrupts cellular microtubules in a concentration-dependent 
manner and a time-dependent manner [29–31], with disruption of cell division. In a recent publication [8], 
our group reported a significant reduction in the mitotic index of lymphocytes exposed to MeHg at 
concentrations of 100 and 1000 μM. 
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Figure 1. Spearman’s correlations between MeHg concentration and mitotic index. 
 
Prolactin acts as a co-mitogenic factor in T and B lymphocytes and in human macrophages through 
specific receptors located on these cells, regulating their proliferation by modulating the expression of 
genes that are essential for cell cycle progression [32]. By binding to the receptor, the PRL stimulation 
leads to a complex signaling cascade that involves kinases and transcription factors for cyclins and 
histones, contributing to cell proliferation and survival [33]. On the other hand, it has been shown that 
prolactin and glutathione levels influence each other [34,35] and that PRL acts by activating the 
glutathione-S-transferase detoxification enzyme [34]. Finally, PRL via the signaling cascade initiates 
the transcription of cyclins, promotes the activation of guanine nucleotides and cytoskeleton 
organization and inhibits apoptosis [32,36]. Figure 2 presents a proposed mechanism for cytoprotective 
activity of prolactin on human lymphocytes exposed to MeHg, which was drawn from the analysis of 
our results and contributions from literature, including information of molecular biology.  
Figure 2. Proposed mechanism for the cytoprotective activity of prolactin in antagonism to 
the cytotoxic and mutagenic effects of methylmercury. 
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In our future studies of this nature, the cells will also be analyzed by the micronucleus test in 
combination with fluorescent in situ hybridization (FISH) using pancentromeric DNA probe, enabling 
the detection of clastogenic and aneugenic changes.  
4. Conclusions  
The combination of parameters—chromosomal aberration, polyploidy, and mitotic index—was 
appropriate for evaluating MeHg mutagenicity and cytotoxicity, the latter being the most striking. 
Prolactin acts as a co-mitogenic factor, regulating proliferation by modulating the expression of genes 
that are essential for cell cycle progression; it also activates detoxification enzymes, promotes 
cytoskeleton organization and inhibits apoptosis. These properties contribute to the protective action of 
PRL against the cytotoxic and mutagenic effects of MeHg. 
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